Pathophysiology of abdominal aortic aneurysms: Insights from the elastase-induced model in mice with different genetic backgrounds

Annals of the New York Academy of Sciences

Volumn 1085, Issue , 2006, Pages 59-73

  Thompson, Robert W ^a   Curci, John A ^a   Ennis, Terri L ^a   Mao, Dongli ^a   Pagano, Monica B ^a   Pham, Christine T N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abdominal aortic aneurysm; Animal models of disease; Cytokines; Elastase; Extracellular matrix; Genetic susceptibility; Genetically altered mice; Inflammation; Proteinases

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; CURCUMIN; DOXYCYCLINE; ELASTASE; ENALAPRIL; GELATINASE B; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LISINOPRIL; LOSARTAN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PANCREATIC ELASTASE; PROTEINASE; PYRROLIDINE DITHIOCARBAMATE; SIMVASTATIN;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; AORTA WALL; ARTERY PERFUSION; CIGARETTE SMOKING; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; GENE DELETION; GENETIC VARIABILITY; HUMAN; INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; REPRODUCIBILITY; TISSUE SECTION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOUSE; PERFUSION; REVIEW;

ANIMALIA; MUS; RATTUS; SUS;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; PANCREATIC ELASTASE; PERFUSION;

EID: 34249319574     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1383.029     Document Type: Conference Paper

References (63)

1. THOMPSON, R.W., P.J. GERAGHTY & J.K. LEE. 2002. Abdominal aortic aneurysms: basic mechanisms and clinical implications. Curr. Prob. Surg. 39: 110-230.
2. ALCORN, H.G., S.K. WOLFSON, JR., K. SUTTON-TYRRELL, et al. 1996. Risk factors for abdominal aortic aneurysms in older adults enrolled in The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 16: 963-970.
3. LEDERLE, F.A., G.R. JOHNSON, S.E. WILSON, et al. 1997. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann. Intern. Med. 126: 441-449.
4. BLANCHARD, J.F. 1999. Epidemiology of abdominal aortic aneurysms. Epidemiol. Rev. 21: 207-221.
5. BLANCHARD, J.F., H.K. ARMENIAN & P.P. FRIESEN. 2000. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am. J. Epidemiol. 151: 575-583.
6. LEDERLE, F.A., D.B. NELSON & A.M. JOSEPH. 2003. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J. Vasc. Surg. 38: 329-334.
7. THOMPSON, R.W. 1996. Basic science of abdominal aortic aneurysms: emerging therapeutic strategies for an unresolved clinical problem. Curr. Opin. Cardiol. 11: 504-518.
8. KOCH, A.E., G.K. HAINES, R.J. RIZZO, et al. 1990. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am. J. Pathol. 137: 1199-1213.
9. PAPAGRIGORAKIS, E., D. ILIOPOULOS, P.J. ASIMACOPOULOS, et al. 1997. Lipoprotein(a) in plasma, arterialwall, and thrombus from patients with aortic aneurysm. Clin. Genet. 52: 262-271.
10. SCHILLINGER, M., H. DOMANOVITS, M. IGNATESCU, et al. 2002. Lipoprotein (a) in patients with aortic aneurysmal disease. J. Vasc. Surg. 36: 25-30.
11. VORP, D.A., P.C. LEE, D.H. WANG, et al. 2001. Association of intraluminal thrombus in abdominal aortic aneurysm with local hypoxia and wall weakening. J. Vasc. Surg. 34: 291-299.
12. SCHILLINGER, M., M. EXNER, W. MLEKUSCH, et al. 2002. Heme oxygenase-1 gene promoter polymorphism is associated with abdominal aortic aneurysm. Thromb. Res. 106: 131-136.
13. MILLER, F.J., JR., W.J. SHARP, X. FANG, et al. 2002. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler. Thromb. Vasc. Biol. 22: 560-565.
14. DALMAN, R.L. 2003. Oxidative stress and abdominal aneurysms: howaortic hemodynamic conditions may influence AAA disease. Cardiovasc. Surg. 11: 417-419.
15. HOLMES, D.R., W. WESTER, R.W. THOMPSON, et al. 1997. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J. Vasc. Surg. 25: 810-815.
16. WALTON, L.J., I.J. FRANKLIN, T. BAYSTON, et al. 1999. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 100: 48-54.
17. BAYSTON, T., S. RAMESSUR, J. REISE, et al. 2003. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J. Vasc. Surg. 38: 354-359.
18. ZHAO, L., M.P. MOOS, R. GRABNER, et al. 2004. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia- dependent aortic aneurysm. Nat. Med. 10: 966-973.
19. LINDHOLT, J.S., H.A. ASHTON & R.A. SCOTT. 2001. Indicators of infection with Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysms. J. Vasc. Surg. 34: 212-215.
20. PEARCE, W.H., I. SWEIS, J.S. YAO, et al. 1992. Interleukin-1 beta and tumor necrosis factor-alpha release in normal and diseased human infrarenal aortas. J. Vasc. Surg. 16: 784-789.
21. KOCH, A., S. KUNKEL, W. PEARCE, et al. 1993. Enhanced production of the chemotactic cytokines interleukin-8 and monocyte chemoattractant protein-1 in human abdominal aortic aneurysms. Am. J. Pathol. 142: 1423-1431.
22. SZEKANECZ, Z., M.R. SHAH, W.H. PEARCE, et al. 1994. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions. 42: 159-162.
23. NEWMAN, K.M., J. JEAN-Claude, H. LI, et al. 1994. Cytokines that activate proteolysis are increased in abdominal aortic aneurysms. Circulation 90: II224-II227.
24. MCMILLAN, W.D. & W.H. PEARCE. 1997. Inflammation and cytokine signaling in aneurysms. Ann. Vasc. Surg. 11: 540-545.
25. JONES, K.G., D.J. BRULL, L.C. BROWN, et al. 2001. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103: 2260-2265.
26. SENIOR, R.M., G.L. GRIFFIN & R.P. MECHAM. 1980. Chemotactic activity of elastin-derived peptides. J. Clin. Invest. 66: 859-862.
27. HINEK, A. 1994. Nature and the multiple functions of the 67-kD elastin-/laminin binding protein. Cell. Adhes. Commun. 2: 185-193.
28. HANCE, K.A., M. TATARIA, S.J. ZIPORIN, et al. 2002. Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. J. Vasc. Surg. 35: 254-261.
29. DOBRIN, P.B. 1999. Animal models of aneurysms. Ann. Vasc. Surg. 13: 641-648.
30. CARRELL, T.W., A. SMITH & K.G. BURNAND. 1999. Experimental techniques and models in the study of the development and treatment of abdominal aortic aneurysm. Br. J. Surg. 86: 305-312.
31. DAUGHERTY, A. & L.A. CASSIS. 2004. Mouse models of abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 24: 429-434.
32. ANIDJAR, S., J.L. SALZMANN, D. GENTRIC, et al. 1990. Elastase-induced experimental aneurysms in rats. Circulation 82: 973-981.
33. ANIDJAR, S., P.B. DOBRIN, M. EICHORST, et al. 1992. Correlation of inflammatory infiltrate with the enlargement of experimental aortic aneurysm. J. Vasc. Surg. 16: 139-147.
34. ANIDJAR, S., P.B. DOBRIN, G. CHEJFEC, et al. 1994. Experimental study of determinants of aneurysmal expansion of the abdominal aorta. Ann. Vasc. Surg. 8: 127-136.
35. PYO, R., J.K. LEE, J.M. SHIPLEY, et al. 2000. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105: 1641-1649.
36. PETRINEC, D., S. LIAO, D.R. HOLMES, et al. 1996. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J. Vasc. Surg. 23: 336-346.
37. CURCI, J.A., D. PETRINEC, S.X. LIAO, et al. 1998. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J. Vasc. Surg. 28: 1082-1093.
38. MOORE, G., S. LIAO, J.A. CURCI, et al. 1999. Suppression of experimental abdominal aortic aneurysms by systemic treatment with a hydroxamate-based matrix metalloproteinase inhibitor (RS 132908). J. Vasc. Surg. 29: 522-532.
39. BIGATEL, D.A., J.R. ELMORE, D.J. CAREY, et al. 1999. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J. Vasc. Surg. 29: 130-138.
40. LEE, J.K., C. BUCKLEY, M. BORHANI, et al. 2003. Endogenous expression of TIMP-1 regulates development of experimental abdominal aortic aneurysms independent of interactions with gelatinase B (abstract). Circulation (Suppl IV) 108: 166.
41. ESKANDARI, M.K., J.D. VIJUNGCO, A. FLORES, et al. 2005. Enhanced abdominal aortic aneurysm in TIMP-1-deficient mice. J. Surg. Res. 123: 289-293.
42. THOMPSON, R.W., S. LIAO & J.A. CURCI. 1998. Therapeutic potential of tetracycline derivatives to suppress the growth of abdominal aortic aneurysms. Adv. Dent. Res. 12: 159-165.
43. THOMPSON, R.W. & B.T. BAXTER. 1999. MMP inhibition in abdominal aortic aneurysms: rationale for a prospective randomized clinical trial. Ann. N.Y. Acad. Sci. 878: 159-178.
44. CURCI, J.A., D. MAO, D.G. BOHNER, et al. 2000. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J. Vasc. Surg. 31: 325-342.
45. PRALL, A.K., G.M. LONGO, W.G. MAYHAN, et al. 2002. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 35: 923-929.
46. BAXTER, B.T., W.H. PEARCE, E.A. WALTKE, et al. 2002. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J. Vasc. Surg. 36: 1-12.
47. VANVICKLE-CHAVEZ, S. J., W.S. TUNG, T.S. ABSI, et al. 2006. Temporal changes in mouse aortic wall gene expression during the development of elastase-induced abdominal aortic aneurysms. J. Vasc. Surg. 43(5): 1010-1020.
48. BARTOLI, M.A., G.-P. SHI, T.L. ENNIS, et al. 2004. Role of cathepsin S in development of experimental abdominal aortic aneurysms (abstract). Arterioscler. Thromb. Vasc. Biol. 24: e64.
49. JOHANNING, J.M., D.P. FRANKLIN, D.C. HAN, et al. 2001. Inhibition of inducible nitric oxide synthase limits nitric oxide production and experimental aneurysm expansion. J. Vasc. Surg. 33: 579-586.
50. LEE, J.K., M. BORHANI, T.L. ENNIS, et al. 2001. Experimental abdominal aortic aneurysms in mice lacking expression of inducible nitric oxide synthase. Arterioscler. Thromb. Vasc. Biol. 21: 1393-1401.
51. STEINMETZ, E.F., C. BUCKLEY, M.L. SHAMES, et al. 2005. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann. Surg. 241: 92-101.
52. NAGASHIMA, H., Y. AOKA, Y. SAKOMURA, et al. 2002. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J. Vasc. Surg. 36: 158-163.
53. SUKHIJA, R., W.S. ARONOW, R. SANDHU, et al. 2006. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am. J. Cardiol. 97: 279-280.
54. HINGORANI, A., E. ASCHER, M. SCHEINMAN, et al. 1998. The effect of tumor necrosis factor binding protein and interleukin-1 receptor antagonist on the development of abdominal aortic aneurysms in a rat model. J. Vasc. Surg. 28: 522-526.
55. JUVONEN, J., H.M. SURCEL, J. SATTA, et al. 1997. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 17: 2843-2847.
56. ROHDE, L.E., L.H. ARROYO, N. RIFAI, et al. 1999. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler. Thromb. Vasc. Biol. 19: 1695-1699.
57. ELIASON, J.L., K.K. HANNAWA, G. AILAWADI, et al. 2005. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation 112: 232-240.
58. GERAGHTY, P.J., B.C. STARCHER, M. BORHANI, et al. 2001. Interleukin-10 deficiency potentiates aortic collagen and elastin degradation in elastase-induced murine aortic aneurysm formation (abstract). Arterioscler. Thromb. Vasc. Biol. 21: 676.
59. BARTOLI, M.A., F. PARODI, J. CHU, et al. 2006. Localized administration of doxycycline suppresses development of experimental abdominal aortic aneurysms. Ann. Vasc. Surg. 20(2): 228-236.
60. BUCKLEY, C., C.W. WYBLE, M. BORHANI, et al. 2004. Accelerated enlargement of experimental abdominal aortic aneurysms in a mouse model of chronic cigarette smoke exposure. J. Am. Coll. Surg. 199: 896-903.
61. BORHANI, M., J.K. LEE, T.L. ENNIS, et al. 2000. Enalapril suppresses experimental aortic aneurysm formation in mice: evidence for a novel molecular mechanism distinct from angiotensin converting enzyme inhibition. Surg. Forum. 51: 397-399.
62. PARODI, F.E., D. MAO, T.L. ENNIS, et al. 2005. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB. J. Vasc. Surg. 41: 479-489.
63. PARODI, F.E., D. MAO, T.L. ENNIS, et al. 2005. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann. Vasc. Surg. 41(3): 479-489.